Fri, Nov 28, 2014, 12:22 PM EST - U.S. Markets close early today in 38 mins. for The day after Thanksgiving

Recent

% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • tradnfrank tradnfrank Nov 15, 2013 10:58 AM Flag

    Here's what all investors should know

    If you're trying to determine whether ImmunoPulse will work or if ONCS is a good investment at $0.28, then just read Brian Nichols's assessment of ImmunoPulse versus TVEC

    ImmunoPulse's objective response of 53% and complete response of 15% is noteworthy and must be considered as a potential threat to Amgen long-term. The reason to consider ImmunoPulse a threat to T-Vec is because of the amount of data OncoSec has produced regarding its technology.

    The company uses electroporation, which is a method of creating electrical currents to increase the uptake of a drug by creating temporary pores in tumors. In testing melanoma and Merkel cell carcinoma, OncoSec has proven this technology effective with no serious side effects. Also, Inovio (INO) uses the same exact technology with its synthetic vaccines, and in 2013 we've seen Inovio trade higher by 280% following data from several electroporation studies. Furthermore, OncoSec uses IL-12 with electroporation, which is a very potent drug.

    Back in March, I interviewed an immunologist, Dr. Rahul Jasuja, who mentioned IL-12, saying it is too toxic to be given systemically. Then, he gave a personal experience, saying:

    "When I was in academia I worked in a lab where I would collect blood samples from patients who had been given IL-12 systemically and the treatment would have modest efficacy, but was extremely harsh and toxic -it would make patients weak, tired, sick, and would create the worst flu-like symptoms. So the quality of life is lousy. Thus, the potential to deliver IL-12 locally has major implications if it shows efficacy and safety in current studies."

    With that said, the purpose of electroporation is to increase the uptake of a drug which then decreases its side effects, as less of the agent is needed. OncoSec is trying to deliver an effective agent, and if it can diminish the side effects then there is reason to believe that ImmunoPulse will be a success. However, I don't know if ImmunoPulse will challenge or overtake T-Vec in treating Stage III cancer, but with data expected in the next couple months, it is worth following nonetheless, with the most to gain and not much to lose.

    Sentiment: Strong Buy

 
ONCS
0.619+0.010(+1.56%)12:04 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.